Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Disoproxil Fumarate to Prevent HBV Reactivation in DLBCL Chemoimmunotherapy
ChiCTR2500110934Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir disoproxil fumarate in hepatitis B (HBV), Hepatitis B reactivation (HBVr) and diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: HBV reactivation rate. Started Oct 2025; status: recruiting.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)Hepatitis B reactivation (HBVr)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500110934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110934.